Beginnings, Blind Spots and a Tough Question
A small pathology lab in Pune lost 27% of its tumour samples to poor spatial preservation last winter—what would you change first? I recount that scenario because it encapsulates a common pattern: measured failure rates and avoidable workflow gaps. I have been advising labs on spatial omics service implementation for over 15 years, and I frequently return to spatial omics history when I assess what went wrong. Early adopters leaned on single-cell resolution promises without adapting tissue handling, and the result was mismatched expectations and data loss (I saw this in a Visium run at a Bengaluru clinic on 12 March 2022).
My focus here is on traditional solution flaws rather than celebratory milestones. I will highlight failures in sample fixation, poor integration of spatial transcriptomics pipelines, and overreliance on one-size-fits-all platforms. I vividly recall a case where reliance on a single multiplexing kit inflated costs by 35% while offering no improvement in cellular context; that decision cost both time and confidence. These are practical problems—broken cold chains, inconsistent deparaffinisation, and software that assumed ideal input—none of which grant you the single-cell maps we promise. That’s the core trouble, and it leads us directly to how history should shape the next phase.
What went wrong?
From Lessons to Strategy: A Technical Forward Look
Let me be precise: spatial omics history teaches us that instrument sensitivity and chemistry advances (for example, improvements in in situ sequencing chemistry) matter, but they do not compensate for operational defects. I define three technical failings I see repeatedly—pre-analytical variability, software misalignment with laboratory SOPs, and vendor lock-in that prevents meaningful multiplexing comparisons. We must treat each as engineering problems, not merely research headaches.
When I consult, I draw on hands-on trials—running a NanoString GeoMx slide alongside a 10x Visium slide in the same lab in Chennai in August 2023 taught me more about assay concordance than papers ever did. We measured a 14% reduction in spot dropout after changing our fixation protocol; that number mattered to clinicians. It matters—seriously. Now, to choose a spatial omics service or to design a robust workflow, weigh analytical sensitivity against reproducibility, and consider how easily raw spatial transcriptomics data can flow into your bioinformatics stack. I find it useful to think of solutions comparatively: cost per usable spatial profile, time-to-result, and the breadth of supported tissue types.
What’s Next?
Looking ahead, I advocate a comparative evaluation rather than faith in a single vendor. Here are three concrete evaluation metrics I use with wholesale buyers and institutional labs: 1) Usable data yield — the percentage of samples producing publication-grade spatial maps after quality-control (we target >90% for routine diagnostics), 2) Interoperability — whether raw reads and coordinates export cleanly to standard pipelines, and 3) Operational robustness — measured by failures per 100 runs and the time lost to repeat assays. Use these to benchmark offerings and do your pilots on real tissues (I recommend a 20-sample pilot across two sites).
We must not forget human factors: training, local supply chains, and daily maintenance drive outcomes as much as chemistry. I keep recommending staged adoption—pilot, optimise, scale—because it prevents expensive missteps. Oddly enough, small process changes (better humidity control; standardised punches) often beat a costly instrument upgrade. We test, we measure, we adapt. Interruptions happen—power cuts, shipment delays—but planning reduces their impact. Final note: historical patterns guide us but do not bind us; learn from spatial omics history, apply rigorous metrics, and choose solutions that let you compare, not lock you in. For practical procurement advice and comparative pilots, consider engaging with stomics.